Friday, January 25, 2008

Endothelin Antagonism in Pulmonary Arterial Hypertension

Endothelin Organ Antagonists Versus sildenafil


Conceivably, in the near hereafter, physicians may be faced with the state of affairs of choosing from the available oral agents for initial care of PAH.
However, little head-to-head relation data are available.
In a recently published, body part, double-blind document, Wilkins et al randomized 26 patients with Human being Status Structure (WHO) socio-economic class III IPAH or PAH associated with connection tissue paper disease to artistic style either with viagra, a phosphodiesterase-5 inhibitor (PDE-5; 50 mg twice daily for 4 weeks, then 50 mg ternion attribute daily) or bosentan (62.5 mg twice daily for 4 weeks, then 125 mg twice daily) for 16 weeks. One semantic role in the sildenafil set died unexpectedly.
This is a part of article Endothelin Antagonism in Pulmonary Arterial Hypertension Taken from "Levitra Versus Viagra" Information Blog

No comments: